Universal Screening of Colorectal Tumors for Lynch Syndrome: a Survey of Patient Experiences and Opinions

Overview

Journal Hered Cancer Clin Pract

Publisher Biomed Central

Specialty Oncology

Date 2024 Sep 5

PMID 39238026

Authors

Alexander T Petterson

Jennifer Garbarini

Maria J Baker

Affiliations

Soon will be listed here.

Abstract

Background: Lynch syndrome represents the most common hereditary cause of both colorectal and endometrial cancer. It is caused by defects in mismatch repair genes, as well as EPCAM. Universal screening of colon tumors for Lynch syndrome via microsatellite instability (MSI) and/or immunohistochemistry (IHC) can identify patients and families at risk to develop further cancers and potentially impact surveillance and treatment options. The approach to implementation of universal screening, taking ethical considerations into account, is critical to its effectiveness, with patient perspectives providing valuable insight.

Methods: Patients whose colon tumors underwent universal screening at Penn State Hershey Medical Center over a period of 2.5 years were mailed a survey on universal screening in 2017. Along with the survey, they received a recruitment letter and a summary explanation of research. The survey included both multiple choice and free-response questions that covered topics including respondent knowledge of Lynch syndrome, attitudes toward universal screening and experiences with the screening protocol as implemented.

Results: Sixty-six of 297 possible patients (22.2%) responded to the survey, including 13 whose screening results raised concern for Lynch syndrome. 75.8% of respondents supported universal tumor screening without informed consent. 92.4% preferred receiving screening results regardless of outcome. Respondents described benefits to screening for themselves and their families.

Conclusions: While broadly supporting universal tumor screening without informed consent, respondents also wanted more information shared about the screening policy, as well as their results. These patient preferences should be one of many factors considered when implementing universal screening and can also inform practices regarding both tumor profiling and universal genetic testing, which is becoming more prevalent.

References

Bombard Y, Rozmovits L, Sorvari A, Daly C, Carroll J, Kennedy E . Universal tumor screening for Lynch syndrome: health-care providers' perspectives. Genet Med. 2016; 19(5):568-574. DOI: 10.1038/gim.2016.150. View

Mukherjee A, McGarrity T, Ruggiero F, Koltun W, McKenna K, Poritz L . The revised Bethesda guidelines: extent of utilization in a university hospital medical center with a cancer genetics program. Hered Cancer Clin Pract. 2010; 8:9. PMC: 2997085. DOI: 10.1186/1897-4287-8-9. View

Chubak B, Heald B, Sharp R . Informed consent to microsatellite instability and immunohistochemistry screening for Lynch syndrome. Genet Med. 2011; 13(4):356-60. DOI: 10.1097/GIM.0b013e31820aee09. View

. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009; 11(1):35-41. PMC: 2743612. DOI: 10.1097/GIM.0b013e31818fa2ff. View

Ceballos R, Newcomb P, Beasley J, Peterson S, Templeton A, Hunt J . Colorectal cancer cases and relatives of cases indicate similar willingness to receive and disclose genetic information. Genet Test. 2008; 12(3):415-20. PMC: 2683753. DOI: 10.1089/gte.2008.0007. View

Perkins A, Haslem D, Goldsberry J, Shortt K, Sittig L, Raghunath S . Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs. Cancers (Basel). 2021; 13(22). PMC: 8616044. DOI: 10.3390/cancers13225612. View

Giardiello F, Allen J, Axilbund J, Boland C, Burke C, Burt R . Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastroenterology. 2014; 147(2):502-26. DOI: 10.1053/j.gastro.2014.04.001. View

Kim M, Kim D, Lee H, Bang S, Seo S, Park K . Universal Screening for Lynch Syndrome Compared with Pedigree-Based Screening: 10-Year Experience in a Tertiary Hospital. Cancer Res Treat. 2022; 55(1):179-188. PMC: 9873326. DOI: 10.4143/crt.2021.1512. View

Hamilton J, Symecko H, Spielman K, Breen K, Mueller R, Catchings A . Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genet Med. 2021; 23(11):2105-2113. PMC: 8556289. DOI: 10.1038/s41436-021-01262-2. View

10.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel W . Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. JAMA Oncol. 2018; 4(6):806-813. PMC: 5885168. DOI: 10.1001/jamaoncol.2018.0104. View

11.

Coughlin S, Heald B, Clark D, Nielsen S, Hatchell K, Esplin E . Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer. JCO Precis Oncol. 2022; 6:e2200517. PMC: 9812641. DOI: 10.1200/PO.22.00517. View

12.

Ramsey M, Tomlinson J, Pearlman R, Abushahin L, Aeilts A, Chen H . Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake. Fam Cancer. 2022; 22(1):91-97. PMC: 9204376. DOI: 10.1007/s10689-022-00300-5. View

13.

Yang Z, Gao J, Zheng J, Han J, Li A, Liu G . Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study. Signal Transduct Target Ther. 2024; 9(1):56. PMC: 10925604. DOI: 10.1038/s41392-024-01762-y. View

14.

Heald B, Plesec T, Liu X, Pai R, Patil D, Moline J . Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. J Clin Oncol. 2013; 31(10):1336-40. PMC: 4878100. DOI: 10.1200/JCO.2012.45.1674. View

15.

Singh H, Schiesser R, Anand G, Richardson P, El-Serag H . Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol. 2010; 8(6):523-9. PMC: 2879470. DOI: 10.1016/j.cgh.2010.03.010. View

16.

Ward R, Hicks S, Hawkins N . Population-based molecular screening for Lynch syndrome: implications for personalized medicine. J Clin Oncol. 2013; 31(20):2554-62. DOI: 10.1200/JCO.2012.46.8454. View

17.

Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J . Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014; 147(2):401-5. DOI: 10.1007/s10549-014-3100-x. View

18.

Hunter J, Zepp J, Gilmore M, Davis J, Esterberg E, Muessig K . Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015; 121(18):3281-9. PMC: 4560979. DOI: 10.1002/cncr.29470. View

19.

Kamel D, Gray C, Walia J, Kumar V . PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. Curr Drug Targets. 2017; 19(1):21-37. DOI: 10.2174/1389450118666170711151518. View

20.

Jarvinen H, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen L, Peltomaki P . Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000; 118(5):829-34. DOI: 10.1016/s0016-5085(00)70168-5. View